Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial
This article has been corrected.
VIEW CORRECTIONPublication: American Journal of Psychiatry
Abstract
Objective:
Suicidal ideation and behavior currently have no quick-acting pharmacological treatments that are suitable for independent outpatient use. Suicidality is linked to mental pain, which is modulated by the separation distress system through endogenous opioids. The authors tested the efficacy and safety of very low dosages of sublingual buprenorphine as a time-limited treatment for severe suicidal ideation.
Method:
This was a multisite randomized double-blind placebo-controlled trial of ultra-low-dose sublingual buprenorphine as an adjunctive treatment. Severely suicidal patients without substance abuse were randomly assigned to receive either buprenorphine or placebo (in a 2:1 ratio), in addition to their ongoing individual treatments. The primary outcome measure was change in suicidal ideation, as assessed by the Beck Suicide Ideation Scale at the end of each of 4 weeks of treatment.
Results:
Patients who received ultra-low-dose buprenorphine (initial dosage, 0.1 mg once or twice daily; mean final dosage=0.44 mg/day; N=40) had a greater reduction in Beck Suicide Ideation Scale scores than patients who received placebo (N=22), both after 2 weeks (mean difference −4.3, 95% CI=−8.5, −0.2) and after 4 weeks (mean difference=−7.1, 95% CI=−12.0, −2.3). Concurrent use of antidepressants and a diagnosis of borderline personality disorder did not affect the response to buprenorphine. No withdrawal symptoms were reported after treatment discontinuation at the end of the trial.
Conclusions:
The time-limited, short-term use of very low dosages of sublingual buprenorphine was associated with decreased suicidal ideation in severely suicidal patients without substance abuse. Further research is needed to establish the efficacy, safety, dosing, and appropriate patient populations for this experimental treatment.
Suicide, with a worldwide annual mortality approaching 1 million, is anteceded by suicidal ideation—thoughts and wishes to kill oneself (1, 2). Although suicidal ideation leads to completed suicide only rarely (2, 3), it cannot be ignored clinically (1, 2), and the management of severely suicidal outpatients remains an enormous clinical challenge (2, 4). Standard antidepressants relieve suicidal ideation, but this may take several weeks, and not all patients respond adequately (1, 4–7). Atypical antipsychotics (8, 9) and lithium (10) have been found to decrease suicidal ideation and/or suicidal behavior in specific patient populations. Ketamine is effective as a quick-acting treatment for suicidal ideation and depression, but necessitates repeated administration under medical supervision (11, 12). Thus, no short-term pharmacological treatments that are suitable for independent outpatient use are currently available for suicidal ideation.
Depression, which is often accompanied by suicidal ideation, shares neurobiological and psychological characteristics with separation distress—the innate, painfully anxious, dysphoric response of young animals and humans to separation from their attachment figures (13–17). Remarkably low, nonsedating doses of opioid analgesics have been found to inhibit separation distress in every animal species tested (15–17). The neuroanatomy of the separation distress system overlaps with the brain’s “pain matrix” and shares some of its neurotransmitter substrates (16, 17). It has been suggested that abrupt cessation of opioid release upon separation from attachment figures contributes to painful separation feelings in animals and humans (16, 17).
Patients with borderline personality disorder, who are exquisitely sensitive to separations, often become suicidal after interpersonal rejections (4, 18), and this patient population has been found to have abnormalities in their endogenous opioid systems (19). Among patients in psychotherapy, most suicidal acts occur after interpersonal losses or rejections (20), and analgesic treatment has been shown to decrease social pain in rejected lovers (21). Social rejection activates the endogenous opioid system in healthy volunteers (22, 23), and this activation is altered in depressed patients (24).
Opioids were widely used to treat depression from about 1850 to 1956 (25). Because of their addictive potential and lethality in overdose, opioids were replaced by standard antidepressants once these became available. However, several studies since then have found them to be effective for treating depression (25–27).
In addition to their association with depression and separation distress, physical and mental pain are associated with suicidality (28–31). Some studies have found mental pain to be the psychological variable most strongly associated with current suicidality, more so than depression and hopelessness (28–30).
In sum, converging lines of evidence point to a connection between separation distress, mental pain, depression, suicidal ideation, and endogenous opioids (14–31). It was therefore hypothesized that opioids in very low dosages might help alleviate suicidal ideation.
Buprenorphine, which is utilized in high dosages for the treatment of opioid use disorder, has a complex pharmacological profile. It is a partial mu agonist and a potent kappa antagonist, and it has several active metabolites (32). Its kappa antagonism may enhance its antidepressant action (16, 27). It causes much less respiratory depression than other opioids and is therefore safer in overdose (32, 33). We aimed to assess the efficacy and safety of ultra-low-dose buprenorphine as a time-limited adjunctive treatment for suicidal ideation.
In animal studies, morphine at 0.125 mg/kg, less than half the dose used for analgesia (34), has been shown to cause potent inhibition of separation distress vocalizations (17). To our knowledge, this is the lowest dose found to produce a robust behavioral response in animals. Given the high sensitivity of the mammalian separation distress system to opioids, we used minimal, subanalgesic dosages of buprenorphine (e.g., 0.1 mg once or twice daily), which were gradually increased. This approach utilized the lowest possible dosages of a potentially addictive drug and minimized side effects that might reduce adherence, increase dropout, and unblind study drug assignment.
Opioids are involved in more deaths than any other drug class in fatal pharmaceutical overdoses in the United States (35). Thus, the lower lethality of buprenorphine and the very low dosages employed in this study were crucial for enabling its independent, home-based use. However, buprenorphine is potentially addictive and possibly lethal (32). We therefore designed this study as a time-limited trial for severely suicidal patients without substance abuse. A treatment duration of 4 weeks was chosen because it roughly corresponds to the interval between the start of antidepressant treatment and the onset of clinical improvement (5–7), and in order to minimize the risk of developing dependence.
Method
Study Design and Participants
We enrolled patients from four medical and psychiatric centers in Israel: Abarbanel Mental Health Center, Bat Yam; Hadassah Medical Center, Jerusalem; Jerusalem Mental Health Center, Jerusalem; and Wolfson Medical Center, Holon. Recruitment was conducted from January 2010 to July 2013. Patients were eligible to participate if they were between 18 and 65 years of age and suffered from clinically significant suicidal ideation, as indicated by a score ≥11 on the self-report version of the Beck Scale for Suicide Ideation (36, 37) for at least 1 week. Exclusion criteria were a lifetime history of opioid abuse, a lifetime diagnosis of schizophrenia, current psychosis, ECT within the past month, substance or alcohol abuse within the past 2 years, and benzodiazepine dependence within the past 2 years. Pregnant or lactating women and patients who suffered from any severe medical condition were also excluded. Psychiatric diagnoses were made according to DSM-IV-TR criteria. The study protocol was approved and monitored by the institutional review boards of all participating centers. All participants provided written informed consent before entering the study.
Randomization
Within each center, randomization was done in a double-blind manner with a web-based schedule (www.randomizer.org), with buprenorphine and placebo assigned in a 2:1 ratio. Sublingual gelatin-based lozenges of 0.1 mg of buprenorphine and identical placebo lozenges were dispensed by pharmacies at each participating center. All study personnel and participants were unaware of participants’ treatment assignment for the duration of the study.
Procedures
Questionnaires were administered once a week. Study psychiatrists met with all participants at baseline and once a week during the trial. At each visit they assessed the severity of participants’ suicidality, screened them for adverse events, and adjusted their medication dosages. An additional appointment with the study psychiatrists was made 1 week after discontinuation of the study medication to screen for possible withdrawal symptoms and verify transition to ongoing care.
Sublingual buprenorphine lozenges were administered on a flexible schedule, beginning with 0.1 or 0.2 mg/day. Once a week, at the decision of the study psychiatrists, the daily dose could be raised in 0.1–0.2 mg increments, to a maximal daily dose of 0.8 mg. The dose was not raised if participants were found to have reached full remission (i.e., had a score of zero on items 4 and 5 of the Beck Scale for Suicide Ideation) or if they experienced significant adverse events. A week’s supply of medication (≤5.6 mg, usually ≤2.8 mg) was not considered to present a high risk for suicide by overdose. Outpatients received the study medication for the following week during their weekly visits, and took it independently at home. Average adherence, measured by pill counts, was 92%. Inpatients received the study medication daily from their hospital staff. Average medication dosages during the trial are summarized in Figure S1 in the data supplement that accompanies the online edition of this article.
Outcome Measures
The primary outcome measure was change from baseline in score on the Beck Scale for Suicide Ideation (36) at the end of the study. Secondary outcome measures were change from baseline in scores on the Beck Depression Inventory II (38) and the Suicide Probability Scale (39) and its hopelessness and worthlessness factors. Mental pain does not have a universally accepted definition (29). Changes in its level were assessed by item 25 of the Suicide Probability Scale (“I feel it would be less painful to die than to keep living the way things are”).
Safety
We consulted and received permission from the Israel Ministry of Health, Division of Clinical Studies, to carry out this trial. Participants’ recruitment was contingent on their being in treatment with a mental health professional, clinic, or hospital that was not part of the study team. In addition to the written informed consent we obtained from all participants, we obtained the approval and collaboration of their treating clinicians. Given the ethical considerations, the study was designed as an adjunctive trial; more than 70% of the participants were on antidepressants, and almost all took some psychotropic medication other than the study drug. With the exception of antidepressants, the treating clinicians could modify the pharmacotherapy their patients were receiving, and could see them as frequently as they deemed necessary, in addition to their weekly appointments with the study psychiatrists. Participants on antidepressants had to have been taking them for at least 28 days, and no changes were allowed during the study period. Table S1 in the online data supplement lists all psychotropic medications taken by study participants during the study. There were no completed suicides during the study period.
Statistical Analysis
To the best of our knowledge, no controlled trial has tested the effects of buprenorphine on suicidal ideation. Based on results from a study on the antisuicidal effects of risperidone (9), we calculated that a sample of 75 participants with a 2:1 randomization ratio would provide 80% power at a 5% significance level to detect a 6.3-point difference between groups in scores on the Beck Scale for Suicide Ideation, assuming a standard deviation of 9.0.
We assessed treatment efficacy with modified intent-to-treat analyses, which included data from all participants who received at least one dose of study drug and had at least one suicidal ideation measurement after baseline. Sensitivity analyses evaluated the robustness of conclusions in relation to missing data. Mixed models for repeated-measures analyses were used to determine the effects of treatment on change from baseline in score on the Beck Scale for Suicide Ideation. The model included treatment group, medication dosage, scheduled visit, treatment-by-visit interaction, baseline score on the Beck Scale for Suicide Ideation, current major depressive episode, and current major depressive episode-by-visit interaction. Missing values were not imputed. An unstructured covariance structure was used.
Secondary outcome analyses, sensitivity analyses, and post hoc baseline-to-endpoint primary outcome analyses were done with and without last observation carried forward. Endpoints were changes from baseline to the end of week 4. We used an analysis of covariance model that included baseline assessment score, treatment group, study medication dosage, and current major depressive episode.
Treatments were compared with two-sided t tests for continuous variables and with Pearson’s chi-square test or Fisher’s exact test, as appropriate, for categorical variables. Analyses were conducted with SPSS, version 20 (IBM, Inc., Armonk, N.Y.). Correlations were calculated using Pearson’s r. Fisher’s r-to-z transformation (http://vassarstats.net/) was used for testing the difference between correlations. All comparisons were two-sided. A p value <0.05 was regarded as significant for all analyses. Safety analyses were done on the safety population, defined as all randomly assigned participants who took at least one dose of study drug, and are presented as descriptive statistics.
Results
Participants
Of 265 patients screened, 88 were randomly allocated to treatment groups—57 to the buprenorphine group and 31 to the placebo group (for a CONSORT diagram, see Figure S2 in the online data supplement ). Of these, 62 (70.5%) received at least one dose of study drug and had a baseline score and at least one postbaseline score on the Beck Scale for Suicide Ideation. Table 1 summarizes the baseline demographic and clinical characteristics of the two treatment groups; there were no significant differences between groups.
| Characteristic | Buprenorphine Group (N=57) | Placebo Group (N=31) | ||
|---|---|---|---|---|
| N | % | N | % | |
| Female | 40 | 70.2 | 23 | 74.2 |
| Suicide attempt during past month | 17 | 29.8 | 8 | 25.8 |
| Current psychiatric hospitalization | 16 | 28.1 | 6 | 19.4 |
| DSM-IV axis IV problem during past year | 31 | 54.4 | 12 | 38.7 |
| Separation during past month | 15 | 26.3 | 6 | 19.4 |
| Psychiatric diagnosesa | ||||
| Borderline personality disorder | 34 | 59.6 | 16 | 51.6 |
| Major depressive disorder | 25 | 43.9 | 13 | 41.9 |
| Adjustment disorders | 12 | 21.1 | 6 | 19.4 |
| Eating disorders | 4 | 7.0 | 4 | 12.9 |
| Posttraumatic stress disorder | 5 | 8.8 | 3 | 9.7 |
| Bipolar disorder | 3 | 5.3 | 3 | 9.7 |
| Fibromyalgia | 1 | 1.8 | 2 | 6.5 |
| Psychotropic medications taken during the studyb | ||||
| Antidepressants | 40 | 70.2 | 22 | 71.0 |
| Benzodiazepines and hypnotics | 31 | 54.4 | 12 | 38.7 |
| Mood stabilizers/anticonvulsants | 10 | 17.5 | 6 | 19.4 |
| Antipsychotics | 14 | 24.6 | 4 | 12.9 |
| Mean | SD | Mean | SD | |
| Age (years) | 38.3 | 12.8 | 36.3 | 15.0 |
| Number of lifetime suicide attempts | 2.3 | 2.5 | 1.4 | 1.7 |
| Number of previous hospitalizations | 1.2 | 1.8 | 0.8 | 1.8 |
| Beck Scale for Suicide Ideation score | 19.7 | 4.9 | 19.6 | 5.4 |
| Suicide Probability Scale score | 92.1 | 18.1 | 91.3 | 16.5 |
| Beck Depression Inventory score | 39.7 | 9.7 | 37.9 | 9.5 |
a
Patients who had more than one psychiatric diagnosis were counted in every diagnosis they had.
b
Patients who were taking more than one class of psychotropic medication were counted in every class of medication they were taking.
Participants in this study were severely suicidal (average baseline score on the Beck Scale for Suicide Ideation, 19.7), and 64.5% of them had made at least one suicide attempt. More than half (56.8%) met criteria for borderline personality disorder. Almost all were clinically unstable, and their ability to cooperate with the study team was compromised, as reflected in a high dropout rate (29.5%) during the first week of treatment.
Primary Outcome Measure
Patients in the buprenorphine group had a greater reduction in Beck Suicide Ideation Scale score than patients in the placebo group, both at the end of week 2 (mean difference=−4.3, 95% CI=−8.5, −0.2; p=0.04) and at the end of week 4 (mean difference=−7.1, 95% CI=−12.0, −2.3; p=0.004) (Figure 1). Sensitivity analysis revealed similar results (mean difference=−5.7, 95% CI=−10.1, −1.4; p=0.01). Concurrent treatment with antidepressants did not affect this response pattern: post hoc comparisons by a series of independent t tests on endpoint results found a greater reduction in Beck Suicide Ideation Scale score in participants who received buprenorphine compared with those who received placebo, whether or not they were also treated with standard antidepressants (Figure 2A). While a diagnosis of borderline personality disorder was associated with a lower response to placebo, it did not attenuate the response to buprenorphine: post hoc comparisons found a greater reduction in Beck Suicide Ideation Scale score in participants who received buprenorphine compared with those who received placebo, whether or not they also had a diagnosis of borderline personality disorder (Figure 2B).
FIGURE 1. Changes From Baseline in Score on the Beck Scale for Suicide Ideation in Patients With Suicidal Ideation Who Received Buprenorphine or Placeboa
a Modified intent-to-treat group. Values are least square means. Lower scores are better.
*p<0.05. **p<0.01.
FIGURE 2. Changes From Baseline to Endpoint (Last Observation Carried Forward) in Score on the Beck Scale for Suicide Ideation in Patients With Suicidal Ideation Who Received Buprenorphine or Placeboa
a Modified intent-to-treat group. Values are least square means. Lower scores are better.
*p<0.05. ***p<0.001.
Secondary Outcome Measures
Patients in the buprenorphine group had a greater reduction in score on the Suicide Probability Scale, an independent measure of suicidal ideation, compared with those who received placebo (mean difference=−10.4, 95% CI=−19.7, −1.0; p=0.03) (Figure 3A). When the analysis was restricted to patients who completed the study (i.e., without last observation carried forward), the scores of the buprenorphine group were lower still, although the difference now fell short of significance (mean difference=−12.0, 95% CI=−24.3, 0.3; p=0.055).
FIGURE 3. Changes from Baseline to Endpoint (Last Observation Carried Forward) in Secondary Efficacy Measures in Patients With Suicidal Ideation Who Received Buprenorphine or Placeboa
a Values are least square means. Lower scores are better. The p values were 0.03, 0.09, 0.03, 0.07, and 0.12 for the Suicide Probability Scale, the Beck Depression Inventory, item 25 of the Suicide Probability Scale, and the hopelessness and worthlessness factors of the Suicide Probability Scale, respectively.
b Item 25 of the Suicide Probability Scale: “I feel it would be less painful to die than to keep living the way things are.”
Patients in the buprenorphine group had lower Beck Depression Inventory scores than those in the placebo group, although the difference did not reach significance (mean difference=−6.1, 95% CI=−13.2, 1.0; p=0.09) (Figure 3B). Restricting the analysis to patients who completed the study yielded similar results (mean difference=−8.3, 95% CI=−16.7, 0.1; p=0.052). Overall, the magnitude of reduction in depressive symptoms was smaller than the reduction in suicidal ideation (see Figure S3 in the online data supplement ). In post hoc analyses, patients who met criteria for major depressive disorder had a lower rate of placebo response and smaller reductions in depressive symptoms compared with nondepressed patients, but these differences were not significant (see Figure S4 in the data supplement ).
Patients in the buprenorphine group had a reduction in level of mental pain, as assessed by item 25 of the Suicide Probability Scale (mean difference=−0.8, 95% CI=−1.5, −0.7; p=0.03) (Figure 3C). Restricting the analysis to patients who completed the study yielded a similar effect (mean difference=−0.9, 95% CI=−1.8, −0.02; p=0.045). Patients in the buprenorphine group had lower scores than those in the placebo group on the hopelessness factor of the Suicide Probability Scale, although the difference fell short of significance (mean difference=−3.5, 95% CI=−7.3, 0.3; p=0.07) (Figure 3D). Differences in changes in the worthlessness factor of the Suicide Probability Scale were not significant (Figure 3E).
The correlation between individual Beck Suicide Ideation Scale and Beck Depression Inventory score changes from baseline to week 4 was strong in both groups, but stronger in the placebo group (r=0.85, 95% CI=0.7, 0.9; p<0.001) compared with the buprenorphine group (r=0.58, 95% CI=0.3, 0.8; p<0.001) (for the difference between correlations, p=0.04) (Figure 4). This difference raises the possibility that treatment with ultra-low-dose buprenorphine may have decreased the tight coupling between changes in depressive and suicidal symptoms. Restricting the analysis to patients who completed the study yielded similar correlations (placebo: r=0.85, 95% CI=0.6, 0.9; p<0.001; buprenorphine: r=0.59, 95% CI=0.3, 0.8; p<0.001); the difference between correlations fell short of significance (p=0.08).
FIGURE 4. Correlations Between Individual Changes from Baseline to Endpoint (Last Observation Carried Forward) in Scores on the Beck Scale for Suicide Ideation and the Beck Depression Inventory in Patients With Suicidal Ideation Who Received Buprenorphine or Placeboa
a For the buprenorphine group, r=0.58, p<0.001; for the placebo group, r=0.84, p<0.001; for the difference between correlations, p<0.05.
Adverse Events
One or more adverse events were reported in 77.2% of participants in the buprenorphine group and 54.8% of those in the placebo group (p=0.03). Among participants in the buprenorphine group, there were more reports of fatigue (49.1% compared with 22.6% in the placebo group), nausea (36.8% compared with 12.9%), dry mouth (29.8% compared with 9.7%), and constipation (26.3% compared with 9.7%). (For frequencies of all adverse events in each group, see Table S2 in the online data supplement .) Despite the high incidence of adverse events, and considering the overall compromised adherence of the study population, the treatment was well tolerated: discontinuation due to adverse events occurred in 22.8% of those who received buprenorphine and in 16.1% of those who received placebo (n.s.). The most common adverse events leading to study discontinuation were nausea, headache, and dizziness.
One or more serious adverse events occurred in 5.3% of the participants who received buprenorphine and in 6.5% of those who received placebo (n.s.). Two participants (one each in the buprenorphine and placebo groups) made a suicide attempt during the study period. One of them was hospitalized for psychiatric observation.
At the end of week 4, the study medication was discontinued without a taper. All participants denied withdrawal symptoms during their follow-up appointment 1 week later. It is possible that in this opioid-naive population, the short duration and low dosages protected against dependence. Alternatively, symptoms may have emerged during the first few days after discontinuation and abated by the time of the follow-up appointment. Among study completers, no exacerbation in suicidality was reported 1 week after medication discontinuation, but clearly a longer follow-up period is required to assess this.
Discussion
In this double-blind, placebo-controlled trial, very low dosages of buprenorphine were associated with decreased suicidal ideation in a group of severely suicidal patients. The choice of ultra-low-dose buprenorphine as a treatment for suicidal ideation was theory driven, based on human and animal studies that have linked suicidality with mental pain and endorphinergic control of the separation distress system (14–31).
With a few notable exceptions (4, 8, 11), pharmacological approaches to the treatment of suicidality have viewed it as an aspect of treating depression (1, 5). The relationship between suicidality and depression is complex (1, 2, 5, 6), and our findings in this study appear to support the view that suicidal ideation and depression may be distinct, although related, phenomena, at least with respect to their response to pharmacotherapy. While higher dosages of buprenorphine than those we used have been found to exert a strong effect on depressive symptoms (26, 27), our findings are in agreement with those of Ballard et al. (11), who found that improvements in suicidal ideation after ketamine infusion were related to, but not completely driven by, improvements in depression and anxiety. Indeed, it was recently suggested that some of ketamine’s psychotropic effects may be mediated by its mu agonism (40).
Two somewhat unexpected findings of this trial require corroboration and further study. First, the effects of ultra-low-dose buprenorphine on suicidal ideation did not differ between patients who were concomitantly treated with antidepressants and those who were not. Second, unlike most antidepressant medication trials, in which a diagnosis of borderline personality disorder has been associated with a poorer clinical outcome (4), patients with and without borderline personality disorder in this trial had similar responses to buprenorphine. This finding, if replicated, raises the possibility that ultra-low-dose buprenorphine treatment addresses a subset of affective symptoms—those associated with painful feelings of rejection and abandonment, and that in this dosage range, it is less active against neurovegetative and other symptoms that are more related to reduced hedonic tone (i.e., in Panksepp’s terminology, ultra-low-dose buprenorphine treatment may attenuate the hyperactivation of the endorphinergic panic/grief system, without reversing the partial shutdown of the aminergic seeking system) (15, 16). As a speculative corollary, in this dosage range, buprenorphine might be more effective against “atypical/borderline” suicidality than against “melancholic” suicidality.
This study had several important limitations. First, its outcome measures were based on self-scored questionnaires. While suicidal ideation is inherently a personal, subjective experience, cross-validation by clinician-scored scales of suicidality, depression, and overall functioning would be beneficial and should be part of any future trial. Second, study participants came from an unstable, severely suicidal population, and a majority of them met criteria for borderline personality disorder. Their ability to comply with the protocol was compromised, as evidenced by relatively high dropout rates in both the placebo and buprenorphine groups. It remains to be seen whether the findings of this study are applicable to more stable, less severely suicidal patients. Third, the dosing regimen of the study medication was flexible and gradual, limiting the inferences that may be drawn about the optimal dosage of buprenorphine to treat suicidal ideation. Fourth, the diagnostic, pharmacological, and therapeutic heterogeneity of the study population and its relatively modest size limited our ability to stratify results by dosage, site, gender, diagnosis, and other potentially important factors. Fifth, this study did not assess nonsuicidal self-injury, which is associated with borderline personality disorder, mental pain, and abnormalities in the endogenous opioid system (23). Sixth, the trial did not include an extended follow-up period, which would have allowed assessment of possible long-term effects, both positive and negative, of this short-term treatment, including the possibility of developing drug craving or rebound suicidality. More research is needed to address all these deficiencies.
Finally, despite its favorable safety profile, buprenorphine is potentially addictive and possibly lethal (32). In our opinion, even in the very low dosages employed in this trial, it should be tested only in individuals who have been screened for the possibility of substance abuse. This is a single, time-limited trial of an experimental treatment for suicidal ideation rather than suicidal behavior, and its results do not support the widespread, long-term, or nonexperimental use of buprenorphine for suicidality.
Conclusions
Human and animal studies have found many links between suicidal ideation, mental pain, depression, and opioid regulation of neurotransmission in the separation distress system (14–31). In this study, the time-limited use of very low dosages of buprenorphine was associated with a decrease in severe suicidal ideation. Further research with longer follow-up is required to establish the safety, dosing, and appropriate patient populations for this experimental short-term treatment.
Acknowledgments
The authors thank their study participants; their colleagues Dr. O. Boneh, Dr. E. Danilovich, Dr. D. Gofrit, Dr. M. Gonzalves, Dr. R. Idelman, Dr. M. Lipot, Dr. H. Oren, Dr. T. Pomerantz, Dr. M. Swartz, Dr. O. Yatziv, and Dr. Y. Zimmerman, who assisted them in this study; L. Kogan, R. Sadan, K. Samet, O. Schnabel, T. Shahar, and L. Yossefi for their help with data collection; and E. Zur, of Super-Pharm Professional Laboratories, for his help in preparing the study medications.
Footnote
ClincalTrials.gov identifier: NCT01046851.
Supplementary Material
File (appi.ajp.2015.15040535.correction.pdf)
- View/Download
- 14.10 KB
File (appi.ajp.2015.15040535.ds001.pdf)
- View/Download
- 286.04 KB
References
1.
Hawton K, van Heeringen K: Suicide. Lancet 2009; 373:1372–1381
2.
O’Connor RC, Nock MK: The psychology of suicidal behaviour. Lancet Psychiatry 2014; 1:73–85
3.
Large M, Smith G, Sharma S, et al: Systematic review and meta-analysis of the clinical factors associated with the suicide of psychiatric in-patients. Acta Psychiatr Scand 2011; 124:18–29
4.
Cardish RJ: Psychopharmacologic management of suicidality in personality disorders. Can J Psychiatry 2007; 52(suppl 1):115S–127S
5.
Sakinofsky I: Treating suicidality in depressive illness, part 2: does treatment cure or cause suicidality? Can J Psychiatry 2007; 52(suppl 1):85S–101S
6.
Mann JJ, Currier D: Medication in suicide prevention: insights from neurobiology of suicidal behavior, in The Neurobiological Basis of Suicide. Edited by Dwivedi Y. Boca Raton, Fla, CRC Press, 2012, pp 425–446
7.
Barbui C, Esposito E, Cipriani A: Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009; 180:291–297
8.
Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152:183–190
9.
Reeves H, Batra S, May RS, et al: Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69:1228–1336
10.
Cipriani A, Hawton K, Stockton S, et al: Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346:f3646
11.
Ballard ED, Ionescu DF, Vande Voort JL, et al: Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res 2014; 58:161–166
12.
Lapidus KAB, Levitch CF, Perez AM, et al: A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014; 76:970–976
13.
Freud S: Inhibitions, symptoms and anxiety (1926 [1925]), in Complete Psychological Works, standard ed, vol 20. London, Hogarth Press, 1959, pp 77–175
14.
Bowlby J. Loss: Sadness and Depression (Attachment and Loss, vol 3; International Psycho-Analytical Library, No 109). London, Hogarth Press, 1980
15.
Panksepp J, Biven L: Archaeology of Mind: The Neuroevolutionary Origins of Human Emotions. New York, Norton, 2012
16.
Panksepp J, Watt D: Why does depression hurt? Ancestral primary-process separation-distress (PANIC/GRIEF) and diminished brain reward (SEEKING) processes in the genesis of depressive affect. Psychiatry 2011; 74:5–13
17.
Panksepp J, Normansell LA, Herman B, et al: Neural and neurochemical control of the separation distress call, in The Physiological Control of Mammalian Vocalizations. Edited by Newman JD. New York, Plenum, 1988, pp 263–300
18.
Gunderson JG: The borderline patient’s intolerance of aloneness: insecure attachments and therapist availability. Am J Psychiatry 1996; 153:752–758
19.
Stanley B, Siever LJ: The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. Am J Psychiatry 2010; 167:24–39
20.
Richards BM: Suicide and internalised reltionships: a study from the perspective of psychotherapists working with suicidal patients. Br J Guid Counc 1999; 27:85–98
21.
Dewall CN, Macdonald G, Webster GD, et al: Acetaminophen reduces social pain: behavioral and neural evidence. Psychol Sci 2010; 21:931–937
22.
Hsu DT, Sanford BJ, Meyers KK, et al: Response of the μ-opioid system to social rejection and acceptance. Mol Psychiatry 2013; 18:1211–1217
23.
Eisenberger NI: The pain of social disconnection: examining the shared neural underpinnings of physical and social pain. Nat Rev Neurosci 2012; 13:421–434
24.
Hsu DT, Sanford BJ, Meyers KK, et al: It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Mol Psychiatry 2015; 20:193–200
25.
Tenore PL: Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis 2008; 27:49–65
26.
Bodkin JA, Zornberg GL, Lukas SE, et al: Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1995; 15:49–57
27.
Ehrich E, Turncliff R, Du Y, et al: Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology 2015; 40:1448–1455
28.
Elman I, Borsook D, Volkow ND: Pain and suicidality: insights from reward and addiction neuroscience. Prog Neurobiol 2013; 109:1–27
29.
Mee S, Bunney BG, Reist C, et al: Psychological pain: a review of evidence. J Psychiatr Res 2006; 40:680–690
30.
Troister T, Holden RR: Comparing psychache, depression, and hopelessness in their associations with suicidality: a test of Shneidman’s theory of suicide. Pers Individ Dif 2010; 49:689–693
31.
Shneidman ES: Suicide as psychache. J Nerv Ment Dis 1993; 181:145–147
32.
Butler S: Buprenorphine: clinically useful but often misunderstood. Scand J Pain 2013; 4:148–152
33.
Dahan A, Yassen A, Romberg R, et al: Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96:627–632
34.
Brodbelt DC, Taylor PM, Stanway GW: A comparison of preoperative morphine and buprenorphine for postoperative analgesia for arthrotomy in dogs. J Vet Pharmacol Ther 1997; 20:284–289
35.
Centers for Disease Control and Prevention: National Vital Statistics System mortality data. 2015. http://www.cdc.gov/nchs/deaths.htm
36.
Beck AT, Steer RA, Ranieri WF: Scale for Suicide Ideation: psychometric properties of a self-report version. J Clin Psychol 1988; 44:499–505
37.
Clum GA, Yang B: Additional support for the reliability and validity of the modified scale for suicidal ideation. Psychol Assess 1995; 7:122–125
38.
Beck AT, Steer RA, Brown GK: Manual for the Beck Depression Inventory–II. San Antonio, Tex, Psychological Corp, 1996
39.
Cull JG, Gill WS: Suicide Probability Scale Manual. Los Angeles, Western Psychological Services, 1988
40.
Sanacora G, Schatzberg AF: Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 2015; 40:259–267
Information & Authors
Information
Published In
History
Received: 23 April 2015
Revision received: 20 August 2015
Revision received: 28 September 2015
Accepted: 21 October 2015
Published online: 18 December 2015
Published in print: May 01, 2016
Authors
Competing Interests
Dr. Yovell reports being listed as an inventor on a patent application for the use of low-dose buprenorphine for suicidality; he has assigned his rights in the patent to the University of Haifa but will share a percentage of any royalties that may be received by the university. The other authors report no financial relationships with commercial interests.
Funding Information
Neuropsychoanalysis Foundation
Institute for the Study of Affective Neuroscience10.13039/501100005868
Hope for Depression Research Foundation10.13039/100006346
Dr. Yovell and Dr. Panksepp were supported by the Hope for Depression Research Foundation (New York). The study was also supported by the Neuropsychoanalysis Foundation and the Institute for the Study of Affective Neuroscience (University of Haifa).Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).